4-Antibody appoints ceo and new board member

To develop more partnerships with corporate pharma

Swiss antibody specialist 4-Antibody has appointed Robert Burns as chief executive and Thomas von Rüden to its board of directors.

Burns has previously held senior positions in the antibody area as ceo of Oslo, Norway-based Affitech and Celldex Therapeutics in the US.

Max Burger, 4-Antibody’s chairman, said Burns is a deal-maker and has the experience to drive 4-Antibody forward to achieve additional multi-target collaborations with corporate pharma to add to the partnership recently put in place with Boehringer Ingelheim.

Von Rüden was formerly ceo at Direvo Industrial Biotechnology in Cologne, Germany. Prior to this, he was chairman of Direvo’s Advisory Board and worked as president and ceo at Direvo Biotech until Bayer Schering acquired the company in September 2008.

Von Rüden also spent six years as cso and executive VP of Business Development with MorphoSys in Munich. Before that he was director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna.

‘We expect Thomas’s knowledge of key trends in pharma antibody discovery and development to add incremental momentum to our pursuit of new corporate partnerships as well as our internal drug discovery and development programmes,’ said Burns.

You may also like

Ingredients

4-Antibody to collaborate with HGS

To discover and develop fully human therapeutic antibodies
Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Long-term collaboration for targets in various disease indications
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines

Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Subscribe now